HROW
Harrow Health, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -6.2% ·
share flow -8.8% ·
net new positions -6.7%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | +1 | 11.44M | $485.62M | +8 | −8 |
| Q1 2026 | 83 | -4 | 11.18M | $394.57M | +6 | −10 |
| Q4 2025 | 87 | 0 | 11.51M | $563.95M | +1 | −1 |
| Q3 2025 | 15 | -1 | 7.56M | $364.09M | +1 | −2 |
| Q2 2025 | 13 | 0 | 7.79M | $237.82M | — | — |
| Q1 2025 | 10 | +1 | 3.25M | $86.47M | +1 | — |
| Q4 2024 | 9 | 0 | 2.94M | $98.57M | — | — |
| Q3 2024 | 8 | +1 | 2.10M | $94.28M | +2 | −1 |
| Q2 2024 | 7 | — | 1.47M | $30.78M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 2.55M | -0.6% | $122.91M | 0.0% | ▼ Trim | 2 | SEC ↗ ×13 |
| 2 | The Vanguard Group ✦ (passive) | 1.87M | +0.1% | $90.13M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 794.28K | +2.7% | $38.27M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 775.64K | -4.3% | $37.38M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 508.12K | -10.1% | $24.48M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 6 | Goldman Sachs Group ✦ | 286.17K | — | $13.79M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 276.56K | -58.6% | $13.32M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 8 | Morgan Stanley ✦ | 141.08K | — | $6.80M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 9 | Wellington Management ✦ | 121.43K | +38.1% | $5.85M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 10 | Renaissance Technologies ✦ | 118.12K | -17.1% | $5.69M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 11 | JPMorgan Chase ✦ | 72.33K | — | $3.49M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 12 | T. Rowe Price ✦ | 24.25K | +6.3% | $1.17M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 7.64K | New | $368,096 | 0.0% | New | 1 | SEC ↗ ×4 |
| 14 | D. E. Shaw & Co. ✦ | 5.50K | -97.4% | $264,845 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 3.84K | +9.8% | $184,971 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $368,096 | 0.0% |
Exited
| Millennium Management | $1.14M | was 0.0% |
| Two Sigma Investments | $991,787 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 216 holders, 21.37M shares, $751.67M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.25K sh · $450,000
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology